Therefore, OPG could exert either anti- or pro-tumoral effects in cells based on whether it binds RANKL or TRAIL, which depends on the relative concentrations of the two cytokines in BC tissue during tumor progression [8,11,44,45]. The gene discussed is TNFRSF11B; the disease is neoplasm.